
    
      This is a double-blind, randomized, placebo-controlled, dose-escalating study. The study
      comprises single dose (Stage I) and multiple dose (Stage II) stages. Stage II will not be
      initiated until completion of Stage I. The interim safety analysis report will be submitted
      to TFDA for an approval for proceeding to Stage II.
    
  